Focus on Quetiapine

Current Medical Research and Opinion

Volumn 15, Issue 3, 1999, Pages 145-151

  Green, Ben ^a  

^a WARRINGTON AND HALTON HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antipsychotics, atypical; Neuroleptics, atypical; Pharmacology; Quetiapine; Schizophrenia

Indexed keywords

BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PHENYTOIN; QUETIAPINE; RIFAMPICIN;

ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; POSITRON EMISSION TOMOGRAPHY; QT INTERVAL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; VERTIGO; XEROSTOMIA;

EID: 0032868282     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999909114085     Document Type: Review

References (24)

1. Arvanitis, L. A. and Miller, B. G. (1997). TI: multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The 'Seroquel' Trial 13 Study Group. Biol. Psych., 42(4), 233-246.
2. Borison, R. L., Arvanitis, L. A. and Miller, B. G. (1996). ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J. Clin. Psychopharmacol., 16(2), 158-169.
3. Gefvert, O., Bergstrom, M., Langstrom, B., Lundberg, T., Lindstrom, L. and Yates, R. (1998) Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine ('Seroquel') in patients with schizophrenia. Psychopharmacol. (Berl.), 135(2), 119-126.
4. Goldstein, J. M. (1998). Low incidence of reproductive/hormonal side effects with 'Seroquel' (quetiapine) is supported by its lack of elevation of plasma prolactin concentrations. Poster presentation, CINP.
5. Gunasekara, N. S. and Spencer, C. M. (1998). Quetiapine - a review of its use in schizophrenia. CNS Drugs, 9(4), 325-340.
6. Hellewell, J. S. E., McKellar, J. and Raniwalla, J. (1998). 'Seroquel': efficacy in aggression, hostility and low mood of schizophrenia. Poster presentation, CINP.
7. Hirsch, S. R., Link, C. G. G., Goldstein, J. M. and Arvanitis, L. A. (1996). ICI 204,636: a new atypical antipsychotic drug. Brit. J. Psych., 168 (Suppl 29), 45-46.
8. Kasper S. (1997). Dopamine D2 receptor binding in typical and atypical neuroleptics. Biol. Psych., 41(75), 67S (Abs 227).
9. Langham, S. and McKellar, J. (1998). Patient satisfaction and acceptability of long-term treatment with 'Seroquel'. Zeneca Pharmaceuticals.
10. Lieberman, J. A. (1996). Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J. Clin.Psych., 57 (Suppl 11), 68-71.
11. Peuskens, J. and Link, C. G. (1997). A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand., 96(4), 265-273.
12. Reynolds, G. P., Tillery, C. , Elliott, J. and Blake, T. J. (1998). Human alpha, adrenoceptor subtypes and their role in antypical antipsychotic drug action. Poster presentation, CINP.
13. Small, J. G., Hirsch, S. R., Arvanitis, L. A., Miller, B. G. and Link, C. G. (1997). Quetiapine in patients with schizophrenia. A high-and low-dose double-blind comparison with placebo. Arch. Gen. Psych., 54(6), 549-557.
14. Swerdlow, N. R., Zisook, D. and Taaid, N. (1994). 'Seroquel' (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: similarities to clozapine. Psychopharmacol. (Berl.), 114(4), 675-678.
15. Yeung, P., Hellewell, J. S. E., Raniwalla, J. et al. (1998). 'Seroquel': extrapyramidal symptoms and tolerability profile in the elderly. Poster presentation, CINP.
16. Aizenberg, D., Zemishlany, Z., Dorfman-Etrog, P. and Weizman, A. (1995). Sexual dysfunction in male schizophrenic patients. J. Clin. Psych., 56(4), 137-141.
17. Casey, D. E. (1996). Side effect profiles of new antipsychotic agents. J. Clin. Psych., 57 (Suppl 11), 40-45; Discussion 46-52.
18. Currier, G. W. and Simpson, G. M. (1998). Antipsychotic medications and fertility. Psych. Serv., 49(2), 175-176.
19. Ereshefsky, L. (1996). Pharmacokinetics and drug interactions: update for new antipsycholics. J. Clin. Psych., 57 (Suppl 11), 12-25.
20. Fabre, L. F., Arvanitis, L., Pultz, J. et al. (1995). ICI 204,636, novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin. Ther., 17(3), 366-378.
21. Fulton, B. and Goa, K. L. (1995). ICI 204,636: an initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs, 4(1), 66-78.
22. Nutt, D. J. (1994). Putting the 'A' in atypical: does alpha-2 adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J. Psychopharmacol., 8, 193-195.
23. Schotte, A., Janssen, P. F., Gommeren, W. et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol. (Berl.), 124 (1-2), 57-73.
24. Wong, J. Y. W., Ewing, B. J., Fabre, L. F. et al. (1996). Multiple-dose pharmacokinetics of 'Seroquel' (ICI 204,636) in schizophrenic men and women. Eur. Psych., 11 (Suppl 4), 429S-430S.